Immunotherapy may play role in treating nonmetastatic gastroesophageal cancer

ROCHESTER, Minn. — Immunotherapy has transformed treatment for patients with stage 4 metastatic esophageal and gastric cancers. In patients with these malignancies, immunotherapy has been shown to prolong survival when patients' tumors exhibit a high expression of an immune-related protein called PD-L1. Researcher s are now investigating whether immunotherapy benefits patients who do not have stage 4 metastatic disease. In these patients, tumors have not spread to distant organs. A study highlighting this research is published…
Source: News from Mayo Clinic - Category: Databases & Libraries Source Type: news